Intraplaque verapamil injection for treatment of Peyronie's disease.
We report our findings on the effects of intraplaque injection of verapamil for the treatment of Peyronie's disease. We followed 11 men with Peyronie's disease in a nonrandomized constant dose study. During our study, four men received testosterone supplementation; five received vitamin E and/or potassium aminobenzoate (potaba) concurrent with verapamil; two received injections of verapamil only. Plaque size decreased significantly in 7 of 11 patients (55%); softening occurred in 6 (55%); 4 of 8 patients (50%) had decreased curvature. Deformities and symptoms did not recur in any patients who reported improvement. Three of 11 (27%) patients failed treatment and elected to undergo surgical correction. All four (100%) of our study participants with pain had complete resolution after intraplaque verapamil injection compared with Levine et al's 91%. We have demonstrated that intraplaque verapamil injection is a promising treatment for Peyronie's disease in that it may circumvent surgical intervention and may be used with concurrent therapies.
Lasser
A
A
Tulane University School of Medicine, New Orleans, La., USA.
Vandenberg
T L
TL
Vincent
M J
MJ
Hellstrom
W J
WJ
D000328:Adult; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010411:Penile Induration / Q000628:therapy*; D016896:Treatment Outcome; D014700:Verapamil / Q000008:administration & dosage*
D002121:Calcium Channel Blockers; D014700:Verapamil